Nektar Shares Rise On Morgan Joseph Analyst View
NEW YORK (AP) — Shares of Nektar Therapeutics jumped Friday after a Morgan Joseph analyst reaffirmed a positive outlook for the developer of drug-delivery technology on its various partnerships.
The stock rose 37 cents, or 6.6 percent, to $6 in midday trading. Shares have traded between $2.45 and $7.13 over the last 52 weeks. Morgan Joseph analyst Shiv Kapoor reaffirmed a "Buy" rating and boosted his price target to $9 from $7, citing the company's momentum in collaborations. Nektar's technology platform is used to enhance the performance of treatments. Its partner UCB received approval in May for Cimzia as a rheumatoid arthritis drug, which helps position Nektar in a market that has billions in revenue. Kapoor also cited the company's partnership with Bayer on an inhaled pneumonia treatment called Amikacin. "Nektar Therapeutics continues to be stigmatized, in our view, by the failure of its inhaled insulin program a few years ago, but we believe CEO Howard Robin is leading a strong comeback by leveraging the company's PEG technology and deep pipeline," Kapoor said, in a note to investors. Nektar saw a dip in revenue after 2007 following Pfizer Inc.'s decision to discontinue selling Exubera inhaled insulin because of disappointing sales. Nektar went through a period of cost-cuts and layoffs.>To order reprints of this article, click here: ReprintsTheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,763.05 | 1,340.64 | 2,902.74 | 19.91 |
Oil *
117.15
|
|
DOWN
127.41 |
DOWN
11.31 |
DOWN
24.49 |
DOWN
0.56 |
10 Yr
1.99%
SPDR Gold
166.86
|
|
-0.99%
|
-0.84%
|
-0.84%
|
-2.74%
|
Data delayed 20 minutes |
Connect with TheStreet